Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion type Assertion NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_head.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion description "[To study the clinical significance of CK20 expression as a marker of systemic metastatic disease it is essential to measure CK20 mRNA levels in hematopoietic tissue with sensitive quantitative RT-PCR.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_provenance.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion evidence source_evidence_literature NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_provenance.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion SIO_000772 11074237 NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_provenance.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion wasDerivedFrom befree-2016 NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_provenance.
- NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_assertion wasGeneratedBy ECO_0000203 NP300231.RA42qxwJakcXl1HAro1VIyc39SoxJpRXfFfZvOFb7Sy8U130_provenance.